Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 55-61

  Freire, Cristina ^a   Podczeck, Fridrun ^b   Ferreira, Dinora ^c   Veiga, Francisco ^a   Sousa, João ^a   Pena, Angelina ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

5 aminosalicylic acid; Colon specific drug delivery; High amylose starches; In vivo drug release

Indexed keywords

AMYLASE; AMYLOSE; BACTERIAL ENZYME; ETHYL CELLULOSE; GELATIN; MESALAZINE;

ANIMAL EXPERIMENT; ARTICLE; COLON; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PELLET; DRUG RELEASE; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; NONHUMAN; RABBIT;

AMYLOSE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLULOSE; COLON; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; INTESTINAL ABSORPTION; MESALAMINE; RABBITS;

EID: 77949530899     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0005     Document Type: Article

References (36)

1. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984; 86: 174-193.
2. Stephen AM, Cummings JH. The microbial contribution to human faecal mass. J Med Microbiol 1980; 13: 45-56.
3. Freire AC et al. Starch based coatings for colonic specific drug delivery: Part I: the influence of heat treatment on the physicochemical properties of high-amylose maize starches. Eur J Pharm Biopharm 2009; 72: 574-586.
4. Freire AC et al. Starch based coatings for colon-specific delivery. Part II: physico-chemical properties and in vitro drug release from high amylose maize starch films. Eur J Pharm Biopharm 2009; 72: 587-594.
5. Milojevic S et al. Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Controll Release 1996; 38: 75-84.
6. Brønsted H, Kopeček J. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm Res 1992; 9: 1540-1545.
7. Tozaki H et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997; 86: 1016-1021.
8. Gao S-Q et al. Biodistribution and pharmacokinetics of colon-specific HPMA copolymer-9-aminocamptothecin conjugate in mice. J Controll Release 2007; 117: 179-185.
9. Tozer TN et al. Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig. Pharm Res 1991; 8: 445-454.
10. Harboe E et al. Macromolecular prodrugs. X. Bioavailability of naproxen after oral administration of dextran-naproxen ester conjugates in rabbits. Farm Sci Ed 1988; 16: 65-72.
11. Harboe E et al. Macromolecular prodrugs. XIV. Absorption characteristics of naproxen after oral administration of a dextran T-70-naproxen ester prodrug in pigs. Int J Pharm 1989; 53: 157-165.
12. Ishibashi T et al. In vivo drug release behavior in dogs from a new colon-targeted delivery system. J Controll Release 1999; 57: 45-53.
13. Ji C et al. In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. J Drug Targeting 2007; 15: 123-131.
14. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 16: 351-380.
15. Gruber P et al. Some biological issues in oral, controlled drug delivery. Adv Drug Del Rev 1987; 1: 1-18.
16. Freire AC et al. Influence of the coating formulation on enzymatic digestibility and drug release from 5-aminosalicylic acid pellets coated with mixtures of high amylose starch and Surelease intended for colon-specific drug delivery. Drug Dev Ind Pharm (in press).
17. Drasar BS et al. The significance of the gut flora in safety testing of food additives, In: Roe FJCE, ed. Metabolic Aspects of Food Safety. New York: Academic Press, 1970: 245-261.
18. Ryde EM, Ahnfelt N-O. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol 1988; 34: 481-488.
19. Bystrowska B et al. Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine. J Pharm Biomed Anal 2000; 22: 341-347.
20. Weber E. Grundriss der Biologischen Statistik, 8th edn. Gustav Fischer Verlag: Jena, 1980.
21. Nobilis M et al. High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. J Chromatogr A 2006; 1119: 299-308.
22. Gidenne T. Effect of fibre level, particle size and adaptation period on digestibility and rate of passage as measured at the ileum and in the faeces in the adult rabbit. Br J. Nutr 1992; 67: 133-146.
23. Harcourt-Brown F, Harcourt-Brown NH. Textbook of Rabbit Medicine. Oxford, UK: Butterworth Heinemann, 2002.
24. Jilge B. Rate of movement of marker particles in the digestive tract of the rabbit. Laboratory Animals 1982; 16: 7-11.
25. Björnhag G. Separation and delay of contents in the rabbit colon. Swed J Agric Res 1972; 2: 125-136.
26. Zhou SY et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999; 27: 479-485.
27. Basit AW et al. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur J Pharm Sci 2004; 21: 179-189.
28. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985; 10: 285-302.
29. van Hogezand RA et al. Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions. Eur J Clin Pharmacol 1992; 43: 189-192.
30. Allgayer H et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 38-41.
31. Peppercorn MA, Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973; 64: 240-245.
32. Schröder H, Cambell DES. Absorption, metabolism and excretion of salicylazosulphapyridine in man. Clin Pharmacol Ther 1972; 13: 539-551.
33. Schiller C et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic ressonance imaging. Aliment Pharmacol Ther 2005; 22: 971-979.
34. McConnell EL et al. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 2008; 60: 63-70.
35. Bondensen S et al. Absorption of 5-aminosalicylic acid from colon and rectum. Br. J Clin Pharmacol 1988; 25: 269-272.
36. Azad Khan AK et al. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892-895.